Tot PP, et al. - Individuals with ≥ 1 claim for statin therapy between January 1, 2010, and December 31, 2010, and ≥ 6 months of baseline data prior to the index date were recruited in a study by the experts to retrospectively examine the real-world impression of elevated triglyceride (TG) levels on cardiovascular (CV) outcomes, medical resource utilization, and medical costs via observational administrative claims data analysis from the Optum Research Database. A significantly larger risk of composite major CV events, nonfatal myocardial infarction, nonfatal stroke, and the requirement for coronary revascularization and not unstable angina or CV death was exhibited in the elevated TG (n = 27,471) vs comparator (n = 32,506) cohorts. Elevated CV risk was controlled with the addition of non–HDL cholesterol to the multivariate model and with high and low HDL cholesterol subgroup analysis. In the elevated TG cohort, total direct healthcare costs and inpatient hospital stays were significantly greater vs the comparator cohort. Hence, when compared with those with well-managed TG (< 150 mg/dL) and HDL cholesterol (> 40 mg/dL) levels, statin-treated individuals with TG levels of ≥ 150 mg/dL had the worse CV and health economic outcomes.